As of 2025-12-29, the Relative Valuation of Travere Therapeutics Inc (TVTX) is (17.86) USD. This relative valuation is based on P/E multiples. With the latest stock price at 38.88 USD, the upside of Travere Therapeutics Inc based on Relative Valuation is -145.9%.
The range of the Relative Valuation is (17.83) - (21.99) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 7.8x - 22.2x | 17.9x |
| Forward P/E multiples | 18.0x - 29.0x | 18.2x |
| Fair Price | (17.83) - (21.99) | (17.86) |
| Upside | -145.9% - -156.6% | -145.9% |
| Date | P/E |
| 2025-12-26 | -40.06 |
| 2025-12-24 | -40.70 |
| 2025-12-23 | -35.73 |
| 2025-12-22 | -36.88 |
| 2025-12-19 | -34.87 |
| 2025-12-18 | -34.85 |
| 2025-12-17 | -34.25 |
| 2025-12-16 | -36.23 |
| 2025-12-15 | -35.13 |
| 2025-12-12 | -35.20 |
| 2025-12-11 | -35.38 |
| 2025-12-10 | -34.74 |
| 2025-12-09 | -34.87 |
| 2025-12-08 | -34.65 |
| 2025-12-05 | -35.37 |
| 2025-12-04 | -35.70 |
| 2025-12-03 | -35.22 |
| 2025-12-02 | -34.35 |
| 2025-12-01 | -35.56 |
| 2025-11-28 | -35.78 |
| 2025-11-26 | -36.64 |
| 2025-11-25 | -36.39 |
| 2025-11-24 | -36.17 |
| 2025-11-21 | -35.05 |
| 2025-11-20 | -35.10 |
| 2025-11-19 | -35.80 |
| 2025-11-18 | -36.38 |
| 2025-11-17 | -35.81 |
| 2025-11-14 | -34.86 |
| 2025-11-13 | -34.25 |
| 2025-11-12 | -36.85 |
| 2025-11-11 | -36.49 |
| 2025-11-10 | -34.74 |
| 2025-11-07 | -32.68 |
| 2025-11-06 | -33.65 |
| 2025-11-05 | -34.07 |
| 2025-11-04 | -34.49 |
| 2025-11-03 | -34.89 |
| 2025-10-31 | -35.53 |
| 2025-10-30 | -29.96 |
| 2025-10-29 | -30.30 |
| 2025-10-28 | -30.12 |
| 2025-10-27 | -30.08 |
| 2025-10-24 | -28.36 |
| 2025-10-23 | -28.45 |
| 2025-10-22 | -27.77 |
| 2025-10-21 | -28.09 |
| 2025-10-20 | -28.18 |
| 2025-10-17 | -27.61 |
| 2025-10-16 | -27.80 |